Sign Up to like & get
recommendations!
1
Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.614363
Abstract: Agonistic monoclonal antibodies (mAbs) targeting the co-stimulatory receptor 4-1BB are among the most effective immunotherapeutic agents across pre-clinical cancer models. However, clinical development of full-length 4-1BB agonistic mAbs, has been hampered by dose-limiting liver toxicity.…
read more here.
Keywords:
human egfr;
egfr targeted;
liver;
1bb agonistic ... See more keywords